DR. ASHLEY ELIZABETH FRITH MD NPI 1730352014

NPI Details

DR. Ashley Elizabeth Frith, MD is a medical oncology internal medicine in Saint Peters, MO with 18 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. DR. Ashley Elizabeth Frith, MD NPI is 1730352014. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

Education
Medical School: UNIVERSITY OF ARKANSAS COLLEGE OF MEDICINE
Graduation Year:2008

The provider's business location address is:

150 ENTRANCE WAY
DIV IM MEDICAL ONCOLOGY, STE 100
SAINT PETERS, MO
ZIP 63376-645
Phone: (800) 647-2098
Fax: (314) 362-3192

The NPI 1730352014 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram (HCPCS:J1442)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, paclitaxel protein-bound particles, 1 mg (HCPCS:J9264)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1561)
• Injection, trastuzumab, excludes biosimilar, 10 mg (HCPCS:J9355)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, pemetrexed, not otherwise specified, 10 mg (HCPCS:J9305)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Injection, doxorubicin hydrochloride, 10 mg (HCPCS:J9000)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Transfusion of blood or blood products (HCPCS:36430)
• Unclassified drugs (HCPCS:J3490)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Red blood cells, leukocytes reduced, irradiated, each unit (HCPCS:P9040)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Collection of blood sample from implanted device (HCPCS:36591)
• Injection, triptorelin pamoate, 3.75 mg (HCPCS:J3315)
• Red blood cells, leukocytes reduced, each unit (HCPCS:P9016)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Injection, alteplase recombinant, 1 mg (HCPCS:J2997)
• Injection of drug or substance into vein (HCPCS:96374)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Declotting of central venous tube (HCPCS:36593)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Biopsy and aspiration of bone marrow sample for diagnosis (HCPCS:38222)

The enumeration date for this NPI number is 4/8/2008 and was last updated on 4/17/2025.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.